Clinical trial
A Phase Ib, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of Rimeporide in Patients With Duchenne Muscular Dystrophy
NCT02710591 is registered in ClinicalTrials.gov with EspeRare Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of Rimeporide in Patients With Duchenne Muscular Dystrophy
- Lead sponsor
- EspeRare Foundation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2016
- Completion date
- February 28, 2018
- Enrollment
- 20 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.